Ethzilla Corp.
ETHZW
NASDAQ Global Market0.01
USD
-0.02
- -
Ethzilla Corp.
ETHZW
(NASDAQ Global Market)
Recent
price
0.01
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ethzilla Corp. operates as a biotechnology and life sciences company specializing in the development, manufacturing, and commercialization of cannabis-derived products and therapeutics. Its core product portfolio includes medical and recreational cannabis formulations; cannabinoid-based pharmaceuticals; wellness products such as oils, tinctures, and topicals; and research services focused on cannabinoid science. The company serves healthcare providers, pharmaceutical partners, and consumer wellness markets primarily across North America, with expanding operations into Europe and other international regions. Founded in 2016 and headquartered in Toronto, Canada, Ethzilla Corp. has recently undertaken significant strategic initiatives including new partnerships with pharmaceutical companies to co-develop cannabinoid drug candidates, launch of proprietary cannabinoid extraction and formulation technologies, and expansion of its product line into novel delivery systems such as transdermal patches and inhalable therapies. In the last two years, Ethzilla has also engaged in several acquisitions to broaden its research capabilities and scale manufacturing infrastructure. These moves reflect a strategic shift from solely cannabis cultivation to a diversified life sciences enterprise focused on innovation in cannabinoid therapeutics and wellness solutions. The company operates through subsidiaries dedicated to cultivation, product development, clinical research, and distribution. Ethzilla's business segments encompass pharmaceutical development, consumer wellness products, and contract research services. Its target customers include healthcare institutions, pharmaceutical companies, licensed cannabis distributors, and direct consumers. As of 2025, Ethzilla continues to invest in clinical trials to substantiate the efficacy of its drug candidates and expand regulatory approvals globally. Overall, Ethzilla Corp. is positioned as an integrated biotechnology company leveraging cannabis science for pharmaceutical innovation, consumer health products, and scientific research, supported by recent expansions and strategic alliances in its evolving industry landscape.